Hot Features
Premium
Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Period:
Draw Mode:
| Volume | 0 |
|
|||||
| News | - |
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Mallinckrodt Plc | MNK | NYSE | Common Stock |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 0.75 | 19:00:00 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 0.75 | 0.75 |
| Trades | Shares Traded | Average Volume |
|---|---|---|
| 0 | 0 | - |
| Last Trade | Type | Quantity | Price | Currency |
|---|---|---|---|---|
| - | 0 | US$ 0.75 | USD |
Mallinckrodt Plc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| US$ 9.88M | - | - | - | -0.20 |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Mallinckrodt News
| Date | Time | Source | News Article |
|---|---|---|---|
| 3/26/2024 | 15:01 | PR Newswire (US) | Mallinckrodt plc Reports Fourth Quarter and Fiscal Year 2023.. |
| 3/11/2024 | 05:52 | PR Newswire (US) | Mallinckrodt Announces Journal Publication of Real-World.. |
| 3/04/2024 | 05:45 | PR Newswire (US) | Mallinckrodt Announces Appointment of Paul O'Neill as.. |
| 3/01/2024 | 07:50 | PR Newswire (US) | Mallinckrodt Announces U.S. FDA Approval of Supplemental New.. |
| 2/02/2024 | 07:45 | PR Newswire (US) | Mallinckrodt Announces Board of Directors and Leadership.. |
| 1/22/2024 | 05:52 | PR Newswire (US) | Mallinckrodt Presents New Data on TERLIVAZ® (terlipressin).. |
| 11/01/2023 | 05:45 | PR Newswire (US) | Mallinckrodt to Present Data on TERLIVAZ® (terlipressin) for.. |
| 10/26/2023 | 05:53 | PR Newswire (US) | Mallinckrodt Presents Latest Health Economics Data on.. |
| 8/30/2023 | 10:54 | PR Newswire (US) | Mallinckrodt Receives Court Approval for "First Day" Motions.. |
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical MNK Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| 1 Month | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| 3 Months | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| 6 Months | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| 1 Year | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| 3 Years | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| 5 Years | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
Mallinckrodt Description
| Mallinckrodt PLC develops, manufactures, markets, and distributes specialty pharmaceutical products and therapies. Its areas of focus include autoimmune and rare diseases in specialty areas like neurology, rheumatology, nephrology, pulmonology and ophthalmology; immunotherapy and neonatal respiratory critical care therapies; analgesics and gastrointestinal products. The company operates its business in two reportable segments namely Specialty Brands which includes innovative specialty pharmaceutical brands; and Specialty Generics which includes niche specialty generic drugs and active pharmaceutical ingredients. It generates maximum revenue from the Specialty Brands segment. Geographically, it derives a majority of revenue from the United States. |
